Patient

Age (yr)/

Weight

Cockcroft

Diagnosis

Pathogen /

Beta-lactam

Initial dosage

Dosage change

Initial

Clinical

Microbiological

No

Gender

(kg)

CLcr (mL･min^-1)

MIC(mg･L^-1)

%T>MIC

efficacy

efficacy

1

59 / M

62.2

76.1

Pneumonia

P.a / 8

CAZ

2g, q8h

1g, q3h

100

Cure

Eradication

2

81 / M

64.7

33.6

Bacteremia

E.cl. / 0.5

MEPM

0.5g, q6h

0.5g, q12h

100

Failure

Undetermined

3

83 / M

43.6

20

Pyelonephritis

P.a. / 2

CAZ

2g, q24h

1g, q12h

100

Cure

Eradication

4

58 / F

60

CVVHDF

Peritonitis

E.co. / 0.5

IPM

0.5g, q12h

0.5g, q24h

100

Cure

Eradication

with cirastatin

5

80 / F

41.8

6.85

Bacteremia

E.co. / 0.5

CAZ

2g, q24h

1g, q24h

100

Undetermined

Eradication

6

54 / M

67.2

143

Bacteremia

P.a. / 8

CFPM

1g, q8h

No

58

Cure

Eradication

7

21 / M

94.2

195

Bacteremia

S.d. / 2

PIPC

4g, q6h

No

100

Cure

Eradication

E. co / 2 

8

84 / F

52.6

66.9

Renal abscess

E.co. / 2

PIPC

4.5g, q8h

No

100

Failure

Persistence

Bacteremia

with tazobactam

9

58 / M

62

CVVHDF

Pyelonephritis

E.co. / 2

PIPC

4.5g, q8h

No

100

Cure

Undetermined

with tazobactam

10

82 / M

74.3

CVVHDF

Pneumonia

E.cl. / 2

PIPC

4.5g, q12h

No

100

Cure

Undetermined

with tazobactam

11

62 / M

61.2

CVVHDF

Bacteremia

C.k. / 1

CAZ

2g, q12h

1g, q12h

100

Cure

Eradication

12

58 / M

51.1

IHD

Prosthetic joint

P.a. / 4

CAZ

1g after IHD

No

100

Undetermined

Eradication

Infection

13

78 / F

60.7

43.1

Pneumonia

P.a. / 1,
A.b. / 4

CAZ

2g, q12h

1g, q12h

100

Cure

Eradication